The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

The novel multi-mechanistic design of SYMBRAVO is a promising advancement, targeting multiple pathways involved in migraine attacks, indicating ... last 6 months: MARK L. JACOBSON (Chief Operating ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...